A carregar...
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients respond, leaving a broad swath of patients who do not derive benefit. Identifying biomarkers to optimally identify patients who will benefit fro...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6858629/ https://ncbi.nlm.nih.gov/pubmed/31730012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0805-8 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|